FPRP/PTGFRN Protein, Mouse (HEK293, His)

The FPRP/PTGFRN Protein inhibits PGF2-alpha binding to its FP receptor, mainly by reducing receptor numbers.It interacts with CD9 and CD81, preventing myotube fusion in myoblasts during muscle regeneration.It also forms a complex with CD9, CD81, and IGSF8, potentially interacting with other tetraspanins like CD63, CD82, and CD151.These interactions highlight its regulatory role in prostaglandin signaling and muscle regeneration.FPRP/PTGFRN Protein, Mouse (HEK293, His) is the recombinant mouse-derived FPRP/PTGFRN protein, expressed by HEK293 , with C-His labeled tag.

The FPRP/PTGFRN Protein functions as an inhibitor by disrupting the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, primarily by reducing the receptor number rather than affecting the affinity constant. Evidence suggests functional coupling with the PGF2-alpha receptor. In myoblasts, this protein forms associations with tetraspanins CD9 and CD81, effectively preventing myotube fusion during muscle regeneration. Additionally, FPRP/PTGFRN participates in a complex that includes CD9, CD81, and IGSF8. Furthermore, it is likely to interact with other tetraspanins such as CD63, CD82, and CD151. These interactions underscore its regulatory role in cellular processes related to prostaglandin signaling and muscle regeneration.

Mouse

HEK293

C-8*His

Q9WV91 (R22-P832)

19221  [NCBI]

Extracellular Domain

RVVRVPAGTLVRVVGTELVIPCNVSDYDGPSEQNFDWSFSSSGSSFVELASTWEVGFPAQLYRERLQRGDILLRRTANDAVELHIKNVQPSDQGHYKCSTPSTDATVQGNYEDTVQVKVLADALVVGPSSRPPPGLSLREGEPFELRCIASTTSPLHTHLALRWELHRGPVHRSILALSHEGRFHPGPGYEQRYHSGDVRLDTVGSDAYRLSVARALSADQGSYRCVVSEWITEQGSWQEIQEKAVEVATVVIQPTALQLAVPRTVSVTEGKDLDLSCNITTDRVDDVRPEVTWYFKKTPDTSLLASHMLARLDRDSLVHSSPHVALSHVDTRSYHLLVRDVSKENSGYYLCLVALWAPGHNRSWHKVAEAMSAPSGVSVTWLEPEYQVYLNASKVPGFSDDPTELQCRVIDTKRLEAGVRLTVSWYYRMTRRNDDVVASELLAVMDGDWTLRYGERSKQRAQDGEFIFSKEHTDTFNFRIQRTTEEDRGNYYCVVSAWTRQRNNSWVKSKDVFSKPVNIFWASEDSVLVVKARQPKPFFAAGNTFEMTCKVSSKNIKSPRYSVLITAEKPVGDLSSPNETKYIISLDQDSVVKLENWTDASRVDGVVLEKVQEDEFRYRMYQTQVSDAGLYRCMVTAWSPIGGSLWREAATSLSNPIEIDFQTSGPTFNASVHSDTPSVTRGDLIKLFCIVTVEGAVLDPDDMAFDVSWFAVHSFGLDKAPVLLSSLDRKGVVTTGQRDWKSTVSLERVSVLEFLLQVHGSEDQDFGNYYCSVTPWVRSPTGSWQREAEIHSRPIFITVKMDVLNAFKYP

Approximately 110-120 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

≥ 95%, as determined by Bis-Tris PAGE.

<1 EU/μg, determined by LAL method.